We are live on ! Find out more
DC

Decheng Capital Portfolio holdings

AUM $661M
1-Year Est. Return 299.97%
This Fund
S&P 500
This Quarter Est. Return
-23.65%
1 Year Est. Return
+299.97%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$356M
AUM Growth
-$110M
Cap. Flow
+$21.8M
Cap. Flow %
6.11%
Top 10 Hldgs %
86.5%
Holding
29
New
1
Increased
2
Reduced
8
Closed
2

Top Buys

Rank Stock Value
1
AARD
Aardvark Therapeutics
AARD
+$44M
2
ACRS icon
Aclaris Therapeutics
ACRS
+$3.79M
3
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$373K

Top Sells

Rank Stock Value
1
ILMN icon
Illumina
ILMN
+$8.99M
2
PHAT icon
Phathom Pharmaceuticals
PHAT
+$5.64M
3
ACLX
Arcellx
ACLX
+$2.33M
4
BNTX icon
BioNTech
BNTX
+$2.24M
5
KRYS icon
Krystal Biotech
KRYS
+$1.98M

Sector Composition

Rank Sector Weight
1 Healthcare 99.99%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VERA icon
26
Vera Therapeutics
VERA
$2.33B
$108K 0.03%
4,495
-45,272
-91% -$1.45M
NUVB.WS
27
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$44K 0.01%
646,057
– –
ATRC icon
28
AtriCure
ATRC
$2.08B
– –
-26,797
Closed -$819K
PHAT icon
29
Phathom Pharmaceuticals
PHAT
$928M
– –
-694,254
Closed -$5.64M
1
2

Similar funds

FAM
Fulcrum Asset Management London, United Kingdom $662M AUM 48.09% 1-Year Est. Return
GC
Globeflex Capital San Diego, California $661M AUM 50.59% 1-Year Est. Return
RCG
Regatta Capital Group El Segundo, California $661M AUM 17.85% 1-Year Est. Return
FM
Freemont Management Vaud, Switzerland $661M AUM 60.48% 1-Year Est. Return
ACM
Arosa Capital Management Miami Beach, Florida $660M AUM 210.26% 1-Year Est. Return
AWA
Artemis Wealth Advisors New York $662M AUM 39.67% 1-Year Est. Return
UCMOK
United Capital Management of KS Salina, Kansas $660M AUM 50.85% 1-Year Est. Return
SHFA
SC&H Financial Advisors Sparks, Maryland $663M AUM 19% 1-Year Est. Return

Decheng Capital's Q1 2025 Portfolio in Review

As of Q1 2025, Decheng Capital held 29 positions worth $356M, down 24% from $466M the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Decheng Capital deployed $21.8M of net new capital in Q1 2025, opening 1 new position and adding to 2 existing holdings. Its largest new stake was Aardvark Therapeutics: 3,917,299 shares worth $29.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

On the sell side, the largest reduction was Illumina, an estimated $8.99M trimmed.

  • Decheng Capital's largest Q1 2025 buy was Aardvark Therapeutics: 3,917,299 shares worth $29.4M.
  • Decheng Capital added most to Aclaris Therapeutics in Q1 2025, an estimated $3.79M increase.
  • Decheng Capital's biggest Q1 2025 reduction was Illumina, cutting an estimated $8.99M.
  • Decheng Capital fully exited Phathom Pharmaceuticals in Q1 2025, selling an estimated $5.64M.
  • Decheng Capital's ten largest holdings make up 86% of its $356M portfolio in Q1 2025.
  • Decheng Capital opened 1 new position and closed 2 in Q1 2025.
  • Decheng Capital's portfolio value fell 24% quarter-over-quarter to $356M.

Based on Decheng Capital's 13F filing for Q1 2025, filed 8 May 2025.